Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Etienne Garin

Showing results (11-20 of 106) with videos related to

Pageof 11
Sort By:
Gastroenterology|April 4, 2017
Does Y90 Radioembolization Prolong Overall Survival Compared With Chemoembolization in Patients With Hepatocellular Carcinoma?Etienne Garin, Xavier Pallard, Julien Edeline
Liver International : Official Journal of the International Association for the Study of the Liver|February 19, 2015
Sorafenib- or 90Y-loaded resin microsphere radioembolization for locally advanced hepatocellular carcinoma, what should we trust?Etienne Garin, Yan Rolland, Julien Edeline
European Journal of Nuclear Medicine and Molecular Imaging|September 5, 2015
Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheresEtienne Garin, Yan Rolland, Sophie Laffont, et al.
International Journal of Molecular Imaging|April 21, 2012
(188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to BedsideNicolas Lepareur, Valérie Ardisson, Nicolas Noiret, et al.
Nature Reviews. Gastroenterology & Hepatology|January 7, 2010
Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclidesJean-Luc Raoul, Eveline Boucher, Yan Rolland, et al.
The Lancet. Gastroenterology & Hepatology|February 14, 2021
Personalised dosimetry for SIRT: new standard or bridge to surgical resection? - Authors' replyEtienne Garin, Lambros Tselikas, Boris Guiu, et al.
The Lancet. Oncology|February 8, 2018
Negative phase 3 study of <sup>90</sup>Y microspheres versus sorafenib in HCCEtienne Garin, Yan Rolland, Boris Campillo-Gimenez, et al.
Pharmacoepidemiology and Drug Safety|July 13, 2011
Meta-analysis of interstitial pneumonia in studies evaluating iodine-131-labeled lipiodol for hepatocellular carcinoma using exact likelihood approachEmmanuel Oger, Audrey Lavenu, Eric Bellissant, et al.
Nuclear Medicine Communications|November 30, 2011
Reduction of β-radiation exposure during preparation of 188Re-labelled Lipiodol for hepatocellular carcinoma treatmentNicolas Lepareur, Sophie Laffont, Valérie Ardisson, et al.
Cardiovascular and Interventional Radiology|February 12, 2022
TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLCBoris Guiu, Etienne Garin, Carole Allimant, et al.
Pageof 11

Showing results (11-20 of 106) with videos related to

Sort By:
Pageof 11
Gastroenterology|April 4, 2017
Does Y90 Radioembolization Prolong Overall Survival Compared With Chemoembolization in Patients With Hepatocellular Carcinoma?Etienne Garin, Xavier Pallard, Julien Edeline
Liver International : Official Journal of the International Association for the Study of the Liver|February 19, 2015
Sorafenib- or 90Y-loaded resin microsphere radioembolization for locally advanced hepatocellular carcinoma, what should we trust?Etienne Garin, Yan Rolland, Julien Edeline
European Journal of Nuclear Medicine and Molecular Imaging|September 5, 2015
Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheresEtienne Garin, Yan Rolland, Sophie Laffont, et al.
International Journal of Molecular Imaging|April 21, 2012
(188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to BedsideNicolas Lepareur, Valérie Ardisson, Nicolas Noiret, et al.
Nature Reviews. Gastroenterology & Hepatology|January 7, 2010
Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclidesJean-Luc Raoul, Eveline Boucher, Yan Rolland, et al.
The Lancet. Gastroenterology & Hepatology|February 14, 2021
Personalised dosimetry for SIRT: new standard or bridge to surgical resection? - Authors' replyEtienne Garin, Lambros Tselikas, Boris Guiu, et al.
The Lancet. Oncology|February 8, 2018
Negative phase 3 study of <sup>90</sup>Y microspheres versus sorafenib in HCCEtienne Garin, Yan Rolland, Boris Campillo-Gimenez, et al.
Pharmacoepidemiology and Drug Safety|July 13, 2011
Meta-analysis of interstitial pneumonia in studies evaluating iodine-131-labeled lipiodol for hepatocellular carcinoma using exact likelihood approachEmmanuel Oger, Audrey Lavenu, Eric Bellissant, et al.
Nuclear Medicine Communications|November 30, 2011
Reduction of β-radiation exposure during preparation of 188Re-labelled Lipiodol for hepatocellular carcinoma treatmentNicolas Lepareur, Sophie Laffont, Valérie Ardisson, et al.
Cardiovascular and Interventional Radiology|February 12, 2022
TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLCBoris Guiu, Etienne Garin, Carole Allimant, et al.
Pageof 11